Patents Assigned to The Ontario Cancer Treatment and Research Foundation
  • Human radioresistance/cell cycle progression gene
    Patent number: 5882862
    Abstract: This invention provides isolated nucleic acids which encode a wildtype and a mutant human homolog of RAD9. This invention also provides purified and mutant wildtype human homologs of RAD9. This invention also provides methods for determining whether a subject has radiosensitivity; for predicting the effect of radiation therapy or chemotherapy on a subject; for detecting whether a subject has a predisposition to cancer; for treating a subject who is radiosensitive and for preventing or treating cancer in a subject who is radiosensitive.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: March 16, 1999
    Assignees: The Trustees of Columbia University in the City of New York, The Ontario Cancer Treatment and Research Foundation
    Inventors: Scott K. Davey, Howard B. Lieberman, Kevin M. Hopkins